A new publication referencing albiglutide appeared on October 5, 2026, in the journal Cureus. The article, titled "GLP-1 Receptor Agonists Across the Coronary Disease Continuum in Type 2 Diabetes: A Systematic Review of Ischemic Events, Revascularization, and Stent Healing," is listed as a systematic review. The publication addresses GLP-1 receptor agonists broadly, with albiglutide noted among the agents discussed in the context of coronary disease in type 2 diabetes. No specific findings, outcomes, or conclusions from the review have been detailed in the available event data. Albiglutide remains classified as an unapproved compound for research purposes only. This entry reflects the existence and publication details of the systematic review as recorded, including its title, journal, and date. No efficacy, safety, or outcome data from the review's content are included here. Readers interested in the specific results, methodology, or conclusions of this systematic review should consult the original article directly through the provided source. For general background on albiglutide, including its development history and regulatory status, see the compound overview.
Albiglutide Featured in New Cureus Systematic Review on GLP-1s
See the full albiglutide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42985248/